INSIGHTS ON CELL & GENE MANUFACTURING AND LOGISTICS
-
![Embryonic stem cell GettyImages-1154785553]( "Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem Cells")
Universalizing Allogeneic Cell Therapies With Cord-Blood-Derived Stem CellsCoeptis Therapeutics' new CSO, Dr. Colleen Delaney, explains why she thinks umbilical cord blood is the best source of starting material for allogeneic cell therapies.
-
![Laboratory-Mouse-GettyImages-172267826]( "Advances In CRISPR Disease Modeling")
Advances In CRISPR Disease ModelingDisease modeling helps us understand disease and create therapies. Learn about the types of disease models, the impact of CRISPR, current challenges, and trends.
-
![IDT Biologika - Vaccine Feature]( "Overcoming Challenges In AAV And LV Viral Vector Manufacturing")
Overcoming Challenges In AAV And LV Viral Vector ManufacturingLearn more about the platform-based scalable suspension process for LVV production and how it is impacting CGTs advancing toward commercialization.
-
![GettyImages-1371706512 cell therapy]( "HEK293T Cell Expansion Protocol Using A Hollow-Fiber Bioreactor System")
HEK293T Cell Expansion Protocol Using A Hollow-Fiber Bioreactor SystemExplore the use of a hollow-fiber bioreactor (HFB) system for the automated expansion of HEK293T cells and a protocol used to help users of the system.
-
![GettyImages-1322464926-visual-inspection-vial-laser]( "How To Lose A Batch In 10 Days")
How To Lose A Batch In 10 DaysInspired by the rom com How to Lose a Guy in 10 Days, this article spotlights the critical missteps that could lead you to lose a batch during the manufacturing process. By identifying these pitfalls, the author guides you toward best practices that will not only save your batches but also improve the quality, efficiency, and reliability of your operations.
-
![Study of DNA molecules-GettyImages-970394890]( "Advancing Policy To Improve Safety And Efficacy For Cell And Gene Therapies")
Advancing Policy To Improve Safety And Efficacy For Cell And Gene TherapiesAchieving greater specificity for cell and gene therapy regulatory guidance is crucial, but even more crucial is establishing guidance informed by patient experience.
-
![Scientist Using Computer In Lab GettyImages-1370154322]( "Scaling Up Your Methods With USP <621> - Part 2: Hardware")
Scaling Up Your Methods With USP <621> - Part 2: HardwareLearn about the hardware changes that allow for scaling and modernization of chromatographic methods and how mismatching particle size and liquid chromatographic systems can result in poor performance.
-
![Cleanroom Scientists At Computer GettyImages-1294339594]( "Scaling Up Your Methods With USP <621> - Part 1: Chemistry")
Scaling Up Your Methods With USP <621> - Part 1: ChemistryExplore the latest updates to the USP <621> guidelines that involve changes to the allowable modifications to gradient methods and updates to system suitability parameters.
-
![Lab Software GettyImages-1180547354]( "Scaling Up Your Methods with USP <621> - Part 3: Software")
Scaling Up Your Methods with USP <621> - Part 3: SoftwareLearn how Empower Software addresses modifications to certain calculations and maintains relevant naming conventions and calculations to help customers update SOPs to prevent disruption to operations.
-
![iStock-968289652-computer-research]( "Monitoring And Determining The Cause Of Antibody Discoloration Using cIEF And EAD")
Monitoring And Determining The Cause Of Antibody Discoloration Using cIEF And EADView a study which provides additional insight into the factors that govern the discoloration of protein therapeutics and the role of AGEs in color change.
